Health TrialsbyHealthPanel

China Liver Cancer Clinical Registry Cohort Database (HEAL)

ConditionLiver Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAnhui Provincial Hospital

About this trial

This study was led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close cooperation with many participating units across the country, to establish a standardized clinical information database of hepatocellular carcinoma cohorts, which will provide a guarantee for conducting high-quality real-world clinical studies and clinical research.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years, no gender limit

Patients without surgery are initially diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of imaging and laboratory tests, or patients with surgery are diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of pathologic tests

Signed informed consent, good compliance, willingness to accept follow-up and provide blood and postoperative pathology residual samples

Disqualifiers

Combination of severe central nervous system disease, respiratory disease, autoimmune disease, chronic renal insufficiency, long-term use of immunosuppressive drugs, combination of severe uncontrolled infections

Concurrent active cardiovascular disease, cerebrovascular accident within 6 months, myocardial infarction, unstable angina pectoris, or congestive heart failure of class II or greater according to the New York Heart Association criteria, severe arrhythmia requiring medication

Pregnant or breastfeeding women

Participation in other therapeutic clinical trials during the course of the patient's illness in which the treatment cannot be specified or information about the treatment cannot be collected

Trial population

Patients diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, combined hepatocellular carcinoma-cholangiocarcinoma, or metastatic liver cancer.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Procedure/Surgery treatment

    Procedure/Surgery

    Routine surgical operations for patients with hepatocellular carcinoma, such as surgical resection, ablation，TACE，HAIC

  • Anti-Tumor Drugs

    Drug

    Use of anti-tumor drugs, e.g., immunologic, targeted, and chemotherapy drugs

Treatment groups

10,000 Participants
are divided into 1 treatment group
Group A: Liver Cancer2 interventions

Trial outcomes

Primary outcomes

1

OS

Time from enrollment to first recorded occurrence of death from any cause

Time frame
10 years

Secondary outcomes

1

RFS

Time from enrollment to the first documented occurrence of local, regional, or metastatic liver cancer or death from any cause, whichever occurs first.

Time frame
10 years
2

Survival time after recurrence

The time from the first documented occurrence of localized, regional, or metastatic liver cancer, whichever occurs first, to death from any cause.

Time frame
10 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Anhui Provincial Hospital

Lead sponsor

Source ClinicalTrials.gov
Apply now